Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Treprostinil Extension in PH-ILD
NCT02633293Phase 3Terminated
- Sponsor
- United Therapeutics Corporation
- Start
- Sep 2016
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of treprostinil in pulmonary hypertension (PH), sponsored by United Therapeutics Corporation. Started Sep 2016; status: terminated.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02633293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633293.